ArticleVeterinary research communications2025
Alleviative potential of dietary essential oils against nickel toxicity triggers neurobehavioral abnormalities, biochemical dysfunction, and histopathological alterations in Nile tilapia.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune-antioxidant responses, autophagy, endoplasmic reticulum stress, resistance to Aeromonas sobria in Nile tilapia under arsenic exposure: The mitigating role of a genistein-fortified diet.Veterinary research communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nickel (Ni) as a waterborne metal pollutant is widespread and harms fish health. In this study, the effects of fortifying diets with 0.1% Melaleuca alternifolia (MO) and 0.1% Ocimum basilicum (BO) essential oils on behaviors, neurotransmitters, liver and kidney functions, biochemical indices, and tissue histological features were studied in Nile tilapia (Oreochromis niloticus) under Ni exposure conditions. A total of 240 fish (27.92 ± 0.22 g) were equally classified into six groups, each with four replicates of 10 fish. The control, MO, and BO groups were fed basal control, 0.1% MO, and 0.1% BO diets, respectively, and reared in Ni-free water. The Ni, Ni + MO, and Ni + BO groups were reared in Ni-medium at a concentration of 3.6 mg/L and fed the same feeding regime as the control, MO, and BO groups, respectively. Ni exposure induced behavioral alterations, including lowered foraging (coefficients of variation, CV = 2.73-14.29%), swimming (CV = 2.95-19.23%), mouth pushing (CV = 9.12-29.37%), spreading of the tail (CV = 3.13-17.32%), and approach (CV = 3.53-11.27%) patterns but increased surfacing (CV = 11.39-23.33%) and resting (CV = 7.14-25%) behaviors. Increased mortality (CV > 30%) and hepato-renal indicators were consequences of Ni exposure. The Ni exposure also depressed brain acetylcholine esterase (AChE) (CV = 0.54-1.10), blood total protein (CV = 3.23-21.87%), albumin (CV = 1.62-13.47%), and globulin (CV = 1.91-24.72%). Histopathological changes were observed in the brain, gills, liver, kidney, and muscle, with detectable Ni residues in the muscle of Nile tilapia. Dietary supplementation with 0.1% MO and/or 0.1% BO significantly improved behavior patterns, blood proteins, and AChE levels under Ni exposure conditions. Hepato-renal indicators and the histology of the studied organs were enhanced, and the residual Ni level was reduced by feeding on the tested diets. Based on the current results, it was concluded that essential oils (0.1% BO and/or 0.1% MO) diets could mitigate the harmful effects caused by Ni exposure in Nile tilapia, which might enhance their future application as effective feed additive candidates in aquaculture.
Indexed as
Identifiers
39964622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.